Olafertinib is under clinical development by Suzhou Neupharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Olafertinib’s likelihood of approval (LoA) and phase transition for Non-Small Cell Lung Cancer took place on 01 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Olafertinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Olafertinib overview

Olafertinib is under development for the treatment of non-small cell lung cancer in patients with EGFR T790M mutation as second-line therapy. It is administered orally. The drug candidates target the epidermal growth factor receptor (EGFR). It is developed based on structure-based drug design platform.

Suzhou Neupharma overview

Suzhou Neupharma operates in pharmaceutical and healthcare industry. It is headquartered in China.

Quick View Olafertinib LOA Data

Report Segments
  • Innovator
Drug Name
  • Olafertinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.